Connect your AI

Novavax NVAX Net proceeds from the exercise of stock-based awards, net of tax withholding

Other financials

Income statement

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

Market cap$1.46B+41.0%

Enterprise value$1.53B+83.6%

P/S2.5×+1.6×

Profitability

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept nvax:NetProceedsFromTheExerciseOfStockBasedAwards.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's net proceeds from the exercise of stock-based awards, net of tax withholding.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Novavax's net proceeds from the exercise of stock-based awards, net of tax withholding?: Novavax (NVAX) reported net proceeds from the exercise of stock-based awards, net of tax withholding of -$8.16M in Q1 2026.
How has Novavax's net proceeds from the exercise of stock-based awards, net of tax withholding changed year-over-year?: Novavax's net proceeds from the exercise of stock-based awards, net of tax withholding decreased by 67.9% year-over-year, from -$4.86M to -$8.16M.